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The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use 
of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y12 inhibitors (i.e. ticagrelor and 
prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in 
pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of 
newer generation P2Y12 inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially 
cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of 
therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, 
the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 
12 months are discussed.
Keywords
P2Y12 inhibitors, Asia-Pacific, acute coronary syndrome, consensus, aspirin, bleeding
Disclosure: This work was funded through the Asian Pacific Society of Cardiology by unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer 
and Roche Diagnostics. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Orbus Neich, Boehringer Ingelheim 
and Pfizer; and research grants from Medtronic, Abbott Diagnostics and Beckmann. DPC reports consulting fee from Asian Pacific Society of Cardiology; support for 
travel to meetings for the study or otherwise from Asian Pacific Society of Cardiology; grants/grants pending from Roche Diagnostics; and payment for development 
of educational presentations including service on speakers’ bureaus from AstraZeneca. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi; and 
grants/grants pending from Daiichi Sankyo. MC reports consulting fee/honorarium from AstraZeneca. KWP reports consulting fee from Arnold & Porter LLP. DQH reports 
consulting fee or honorarium from AstraZeneca; and support for travel to meetings for the study or otherwise from AstraZeneca. SJ reports honorarium from Medtronic; 
and travel/accommodation expenses from Medtronic and Edward Lifesciences. DAJ reports board membership at Menarini; honorarium from AstraZeneca; and travel/
accommodation expenses from Boston Scientific. DT reports honorarium from The Meeting Lab; and travel/accommodation expenses paid to institution from The Meeting 
Lab. GM reports research grants to the institution or consulting/lecture fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, 
Axis-Santé, Bayer, Boston-Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Idorsia, Elsevier, Fédération 
Française de Cardiologie, Frequence Medicale, ICAN, Lead-Up, Medtronic, Menarini, MSD, Pfizer, Quantum Genomics, Sanofi, SCOR global life, Servier and WebMD. All 
other authors have no conflicts of interest to declare.
Acknowledgement: Medical writing support was provided by Ivan Olegario of MIMS Pte Ltd. 
Received: 20 October 2020 Accepted: 4 November 2020 Citation: European Cardiology Review 2021;16:e02. DOI: https://doi.org/10.15420/ecr.2020.40
Correspondence: Jack Wei Chieh Tan, National Heart Centre, 5 Hospital Dr, Singapore 169609, Singapore. E: jack.tan.w.c@singhealth.com.sg
Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial 
purposes, provided the original work is cited correctly.
2020 Asian Pacific Society of Cardiology Consensus Recommendations 
on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region
Jack WC Tan,1,2 Derek P Chew,3 Muhamad Ali SK Abdul Kader,4 Junya Ako,5 Vinay K Bahl,6 Mark Chan,7  
Kyung Woo Park,8 Praveen Chandra,9 I-Chang Hsieh,10 Do Quang Huan,11 Sofian Johar,12 Dafsah Arifa Juzar,13  
Byeong-Keuk Kim,14 Cheol Whan Lee,15 Michael Kang-Yin Lee,16 Yi-Heng Li,17 Wael Almahmeed,18  
Eric Oliver Sison,19 Doreen Tan,20 Yu-Chen Wang,21 Shiuan Jong Yeh22 and Gilles Montalescot23,24,25
1. National Heart Centre, Singapore; 2. Sengkang General Hospital, Singapore; 3. College of Medicine and Public Health, Flinders University, 
Adelaide, Australia; 4. Hospital Pulau Pinang, Penang, Malaysia; 5. Kitasato University and Hospital, Tokyo, Japan; 6. All India Institute of 
Medical Sciences, New Delhi, India; 7. National University Hospital, Singapore; 8. Seoul National University Hospital Internal Medicine, Seoul, 
South Korea; 9. Medanta – The Medicity, Gurgaon, India; 10. Chang Gung Memorial Hospital, Taoyuan City, Taiwan; 11. Heart Institute of Ho 
Chi Minh City, Ho Chi Minh, Vietnam; 12. Ripas Hospital, Brunei; 13. Universitas Indonesia, Jakarta, Indonesia; 14. Yonsei University College of 
Medicine, Seoul, South Korea; 15. Asan Medical Center, University of Ulsan, Seoul, South Korea; 16. Queen Elizabeth Hospital, Hong Kong, 
China; 17. National Cheng King University Hospital, Tainan, Taiwan; 18. Cleveland Clinic Abu Dhabi, United Arab Emirates; 19. University of the 
Philippines-Philippine General Hospital, Manila, Philippines; 20. Khoo Teck Puat Hospital, Singapore; 21. China Medical University Hospital, 
Taichung City, Taiwan; 22. Taipei Medical University, Taipei, Taiwan; 23. Sorbonne University, Paris, France; 24. ACTION Study Group, France; 
25. Pitié-Salpêtrière Hospital (AP-HP), Paris, France
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use
EUROPEAN CARDIOLOGY REVIEW
Access at: www.ECRjournal.com
The management of acute coronary syndrome (ACS) varies across the 
Asia-Pacific region.1 In particular, there is significant heterogeneity 
regarding the use of reperfusion techniques and pharmacological 
management.1 For example, thrombolysis is commonly used for 
reperfusion in China, India and parts of South-East Asia, whereas 
percutaneous coronary intervention (PCI) and coronary artery bypass 
grafting (CABG) are more common in Japan, Korea, Taiwan, Australia and 
New Zealand.1
Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin is 
generally recommended for at least 1 year following an ACS, or longer for 
patients with a high ischaemic/low bleeding risk.2,3 However, there is 
considerable variation in DAPT duration across Asia and a one-size-fits-all 
approach based on Western guidelines may not be appropriate for Asian 
populations.4 For example, genetic polymorphisms (i.e. polymorphisms 
affecting CYP2C19 function) associated with a slower rate of bioactivation 
of clopidogrel have a substantially higher prevalence in Asian people 
(29–60%) than Caucasian people (15%).5 Furthermore, the ‘East Asian 
paradox’ results in a different benefit–risk profile, where the risk of 
ischaemic events is lower, and bleeding higher, than Western populations, 
despite higher average on-treatment platelet reactivity.6,7 Nevertheless, 
data generated from Asian patients are limited and rarely incorporated 
into major international guidelines.
Newer oral therapies have been developed offering faster onset, more 
potent platelet inhibition and lower response variability than clopidogrel. 
Ticagrelor, a cyclo-pentyl-triazolo-pyrimidine, has a reversible, direct-
acting mechanism of action that is not impacted by CYP2C19 
polymorphisms and prasugrel, a thienopyridine prodrug, is less 
susceptible to CYP2C19 polymorphisms than clopidogrel.8–11 We aim to 
summarise key evidence and provide recommendations on the use of 
P2Y12 inhibitors in Asian patients.
Methods
The Asian Pacific Society of Cardiology (APSC) convened a panel of 22 
experts from 13 countries in Asia-Pacific with clinical and research 
expertise in the use of P2Y12 inhibitors, to develop consensus statements 
on the use of these class of drugs in ACS patients in the Asia-Pacific 
region. The experts were members of the APSC who were nominated by 
national societies and endorsed by the APSC consensus board. After a 
comprehensive literature search, with particular focus on Asian-centric 
studies, selected applicable articles were reviewed and appraised using 
the Grading of Recommendations Assessment, Development, and 
Evaluation system, as follows: 
1. High (authors have high confidence that the true effect is similar to 
the estimated effect).
2. Moderate (authors believe that the true effect is probably close to the 
estimated effect).
3. Low (true effect might be markedly different from the estimated 
effect).
4. Very low (true effect is probably markedly different from the 
estimated effect).12 
The available evidence was then discussed during two consensus 
meetings. Consensus statements were developed during these meetings, 
which were then put to an online vote. Each statement was voted on by 
each panel member using a three-point scale (agree, neutral or disagree). 
Consensus was reached when 80% of votes for a statement were agree 
or neutral. In the case of non-consensus, the statements were further 
discussed using email, then revised accordingly until the criteria for 
consensus was reached.
Results and Discussion
The efficacy and safety of ticagrelor was demonstrated in the Study of 
Platelet Inhibition and Patient Outcomes (PLATO), which enrolled more 
than 18,500 patients with an ACS.13 The risk of cardiovascular (CV) death, 
MI or stroke with ticagrelor decreased by 16% compared with clopidogrel 
after 12 months, with benefit being observed within 30 days and accruing 
throughout the study period. Notably, ticagrelor reduced the risk of both 
CV death and recurrent non-fatal MI versus clopidogrel. 
The PEGASUS-TIMI 54 study subsequently demonstrated a benefit when 
extending ticagrelor-based DAPT for up to 3 years.14
No difference in PLATO- or TIMI-defined major bleeding was observed 
between ticagrelor or clopidogrel in the PLATO study, but non-CABG-
related and TIMI-defined major bleeding was significantly increased in 
PLATO and PEGASUS-TIMI 54, respectively.13,14 Ticagrelor was also 
associated with an increased risk of dyspnoea.13
No interaction between Asian/non-Asian ethnicity and efficacy was 
observed in PLATO.15 However, the overall event rate was higher in Asian 
patients, despite a similar bleeding risk.15 Southeast Asian patients also 
appeared to experience higher rates of ischaemic events and bleeding 
than East Asian patients.15
Two randomised but underpowered studies, PHILO and TICA KOREA, 
compared ticagrelor versus clopidogrel in Asian patients.16,17 The risk of 
bleeding and ischaemic events was increased among East Asian patients 
with ACS from Japan, Taiwan, and South Korea in PHILO.16 Likewise, in 
TICA KOREA, the incidence of clinically significant bleeding was 
significantly higher with ticagrelor versus clopidogrel among Koreans 
hospitalised for ACS with planned invasive management, while the 
incidence of CV death, MI, or stroke was also numerically higher in the 
ticagrelor arm.17
TRITON-TIMI 38 compared prasugrel with clopidogrel in patients with an 
ACS scheduled to undergo PCI; prasugrel reduced the risk of CV death, MI 
or stroke by 19% compared with clopidogrel, but the incidence of non-
CABG-related TIMI major and life-threatening bleeding were significantly 
increased.18 As a result, a reduced 5 mg dose is indicated for patients aged 
≥75 years or with body weight <60 kg, and prasugrel is contraindicated for 
those with a history of stroke or transient ischaemic attacks.8 
The PRASFIT-ACS study on Japanese patients with ACS undergoing PCI is 
the only randomised trial comparing the outcomes with prasugrel and 
clopidogrel in an exclusively Asian population.19 Notably, patients were 
administered markedly lower doses of prasugrel (20 mg loading/3.75 mg 
daily maintenance dosing), yet the incidence of CV death, MI or stroke 
was reduced by 23% at 24 weeks without significantly increasing non-
CABG-related major bleeding. While the reduced risk of ischaemic events 
was not statistically significantly different, the result was comparable with 
the TRITON-TIMI 38 trial, although follow-up was shorter.18,19
Only one randomised head-to-head comparison of prasugrel and 
ticagrelor has been performed – the Intracoronary Stenting and 
Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-
REACT) 5 trial.20 In this open-label study the risk of CV death, MI, or stroke 
was 36% higher with ticagrelor than prasugrel at 1 year (9.3% versus 6.9%; 
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use
EUROPEAN CARDIOLOGY REVIEW
Access at: www.ECRjournal.com
p=0.006), while rates of major bleeding were similar.20 However, this 
result must be interpreted with caution because of the open-label design, 
high rate of drug discontinuation, an unexpectedly low rate of MI in the 
prasugrel arm and allowance for telephone follow-up of participants.20 No 
head-to-head studies comparing ticagrelor and prasugrel have been 
performed in Asian patients.
Overall, DAPT incorporating ticagrelor or prasugrel, instead of clopidogrel, 
reduces the risk of ischaemic events, but may increase the risk of 
bleeding.13,18 However, studies of ticagrelor and prasugrel have largely 
been performed in Western populations that may have a differing risk 
profile for both ischaemic and bleeding events versus Asian patients. 
Therefore, targeted guidance for physicians prescribing ticagrelor or 
prasugrel to Asian patients with an ACS are necessary.
ST-elevation Acute Coronary Syndrome
Statement 1. A 12-month duration of therapy for ticagrelor (180 mg 
loading and 90 mg twice-daily maintenance dose) and prasugrel 
(60 mg loading and 10 mg daily) are effective and safe in the 
prevention of adverse cardiovascular events among patients with 
ST-elevation MI (STEMI) and are recommended in patients who are 
undergoing primary PCI.
Level of evidence: High.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Statement 2. If aspirin and clopidogrel are introduced early in 
thrombolysis, a switch to ticagrelor should be considered the next 
day or after 8 hours. 
Level of evidence: High.
Level of agreement: 90.9% agree, 9.1% neutral, 0% disagree.
Both ticagrelor and prasugrel significantly reduce the risk of CV death, MI 
or stroke in patients with an ST-elevation ACS (STE-ACS) versus 
clopidogrel.21,22 However, ticagrelor and prasugrel have not been 
extensively studied in Asian patients with STE-ACS, so the use of 
clopidogrel should not be disregarded.
Antiplatelet therapy should be initiated upon diagnosis of STE-ACS, ideally 
before or while a patient is being transported to the hospital for primary 
PCI, in the absence of contraindications (e.g. severe bleeding; Figure 1).2,3 
Prehospital administration of ticagrelor (i.e. in transit) to patients 
presenting with an STE-ACS is possible, but does not offer significant 
benefits beyond a reduced risk of stent thrombosis.23 Aspirin (300 mg or 
325 mg loading dose and 75 mg or 81–100 mg maintenance dose) should 
be initiated for all STE-ACS patients prior to or at hospital presentation.2,3 
For patients initially managed using thrombolysis, US and European 
guidelines recommend administering clopidogrel immediately, because 
ticagrelor was administered >24 hours after a STE-ACS in the PLATO 
study.2,24 The European guidelines note switching from clopidogrel to 
prasugrel or ticagrelor may be considered after 48 hours for patients who 
receive fibrinolysis and subsequently undergo PCI.24
No significant differences in the rate of TIMI major bleeding after 30 days 
in patients have been observed in STEMI patients treated with ticagrelor 
or clopidogrel after undergoing fibrinolysis in an approximately 8-hour/
next-day timeframe.25 Likewise, rates of major bleeding were similar after 
12 months, indicating that early switching from clopidogrel to ticagrelor 
after fibrinolysis is feasible.26 The use of prasugrel after fibrinolysis for 
STEMI has not been well studied, so no recommendation is made.
Non-ST-elevation Acute Coronary Syndrome
Statement 3. Ticagrelor (180 mg loading and 90 mg twice daily 
maintenance dose) is recommended in patients with non-ST-
elevation ACS (NSTE-ACS). In patients receiving an early invasive 
strategy (<12 hours), pre-treatment may not be mandated.
Level of evidence: High.
Level of agreement: 100% agree, 0.0% neutral, 0.0% disagree.
Statement 4. Prasugrel (60 mg loading and 10 mg daily) is 
recommended only in patients who have undergone percutaneous 
coronary intervention. In countries where a reduced loading or 
maintenance dose is approved, a reduced dose may be considered. 
Pre-treatment is not recommended.
Level of evidence: High.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Statement 5. Unless bleeding risk is high, a minimum of 6 months of 
DAPT is recommended to reduce ischaemic risk in NSTE-ACS. 
Level of evidence: Moderate.
Level of agreement: 86.4% agree, 4.5% neutral, 9.1% disagree.
This consensus statement recommends the use of P2Y12
 inhibitors as part 
of DAPT as a cornerstone intervention for NSTE-ACS (Figure 2), in a similar 
manner to Western guidelines.27 
The efficacy and safety profile of ticagrelor in patients with NSTE-ACS is 
consistent with the overall PLATO study population.28 While a study in 
Chinese patients with NSTE-ACS undergoing PCI suggested that doubling 
the ticagrelor loading dose may achieve faster onset of platelet inhibition 
without an increase in adverse events, this is unlikely to be associated 
with a clinically meaningful benefit and is inconsistent with the approved 
ticagrelor label.9,10,29
Figure 1: Treatment Algorithm for Patients with STEMI 
DAPT = dual antiplatelet therapy; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI.
STEMI patient eligible for
reperfusion therapy




8 hours, or until
the next day
For thrombolysis
Provide written and verbal information, advice, support and treatment
on related conditions and secondary prevention (including lifestyle 
advice), as relevant. In select patients, consider extending DAPT.  
Take to cardiac catheterisation
laboratory for primary PCI
DAPT regimen with aspirin and:
First choice: ticagrelor/prasugrel
Second choice: clopidogrel
DAPT for 12 months
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No benefit has been observed versus placebo when initiating P2Y12 
antiplatelet therapy when invasive procedures for ACS are planned within 
12 hours of presentation, so routine pre-treatment prior to early invasive 
intervention is not mandated.30
The efficacy and safety of prasugrel was only investigated in patients who 
underwent PCI in TRITON-TIMI 38, and the approved indication has been 
limited accordingly.8,11,18 Reduced prasugrel dosing (20 mg loading/3.75 mg 
daily maintenance dosing) has demonstrated improved efficacy compared 
with clopidogrel in Japanese patients with ACS without significantly 
increasing non-CABG-related major bleeding, supporting lower indicated 
dosing in some Asian countries.19
Prasugrel pre-treatment prior to invasive procedures is not recommended 
because of the increased risk of bleeding without reducing the risk of 
ischaemic events.31
A net clinical benefit is expected for all patient groups with at least 6 
months of DAPT after an ACS.32 However, for patients with a high risk of 
bleeding, the reduced risk of ischaemic events needs to be weighed 
against the risk of bleeding after 6 months.32 Furthermore, as pointed out 
by some panellists, the DAPT study evaluated a treatment duration of at 
least 12 months.
Bleeding Risk
Statement 6. There is no specific bleeding risk calculator 
recommended for use in Asian populations. 
Level of evidence: Very low.
Level of agreement: 95.5% agree, 4.5% neutral, 0.0% disagree.
Statement 7. Ticagrelor or prasugrel in combination with aspirin 
should be considered as first-line for NSTE-ACS patients at high risk 
of ischaemia, unless patient has prior history of bleeding or is above 
85 years old. Adjust the duration of therapy based on bleeding risk. 
Level of evidence: Low.
Level of agreement: 72.8% agree, 0.0% neutral, 13.6% disagree.
Statement 8. Proton pump inhibitors (PPIs) may be considered for 
use in patients with high risk of bleeding. However, other causes of 
bleeding or anaemia should be investigated. 
Level of evidence: Moderate.
Level of agreement: 100.0% agree, 0.0% neutral, 0.0% disagree.
Statement 9. A radial access should be considered as default 
strategy for patients undergoing catheterisation.
Level of evidence: High.
Level of agreement: 95.5% agree, 4.5% neutral, 0.0% disagree.
Statement 10. Among patients on DAPT who are scheduled to 
undergo non-cardiac surgery, consider the risk associated with 
stopping DAPT or continuing aspirin alone versus delaying surgery 
until completion of 6 months of DAPT post-MI. A joint discussion 
between cardiologist and proceduralist regarding the risk of bleeding 
versus an ischaemic event following cessation of DAPT should be 
considered. Stop ticagrelor and clopidogrel 5 days, and prasugrel 7 
days, prior to surgery.
Level of evidence: Moderate.
Level of agreement: 95.5% agree, 4.5% neutral, 0.0% disagree.
A recommendation for a specific bleeding risk score was not 
recommended in Asia because there is no validated bleeding risk 
calculator for Asian patients. Post-ACS bleeding risk tends to be 
overestimated compared with ischaemic risk in Asian patients.33 
Therefore, an individualised assessment of the benefit-risk ratio of DAPT 
should be performed on the basis of a patient’s medical history, physical 
examination, and laboratory parameters.
Both ticagrelor and prasugrel have demonstrated improved efficacy 
versus clopidogrel in patients with ACS undergoing revascularisation, 
although some panellists have highlighted that the data for prasugrel is 
only for PCI.18,34,35 No difference in the risk of major bleeding was observed 
between ticagrelor and clopidogrel in the Asian subgroup analysis of the 
PLATO study or in several real-world comparisons in Asian 
populations.15,36–38 However, other studies have suggested there is an 
increased risk of major bleeding with ticagrelor compared with clopidogrel 
in East Asian patients.16,17,39–43 The risk of bleeding with prasugrel has also 
been reported to be higher than for clopidogrel in Korean patients.44 The 
risk of any bleeding has been reported as being comparable between 
ticagrelor and prasugrel in East Asian patients.43 Therefore, duration of 
therapy should be based on a perceived on-going net clinical benefit.
No increase in the risk of bleeding or ischaemic events has been observed 
in patients administered ticagrelor or prasugrel versus clopidogrel alongside 
a PPI.45–47 However, PPI administration is associated with lower clopidogrel 
active metabolite levels and ex vivo-measured platelet inhibition.48
Bleeding complications may also be reduced with the use of a transradial 
access during PCI. A 2020 meta-analysis that included 18 randomised 
controlled trials (n=21,669) found that among patients with ACS who have 
undergone PCI, transradial access decreased the risk of major bleeding 
by 38% (p<0.001) compared to a transfemoral route.49 Radial access was 
also associated with a 25% lower risk of all-cause mortality (p=0.002). 
Both results were consistent across subgroups except in those that used 




2. Discontinue ticagrelor or clopidogrel 5 days, and prasugrel 7 days,
 before CABG for patients undergoing revascularisation
3. Ticagrelor/prasugrel (or clopidogrel as second choice) for up to 
 12 months
Prasugrel is not indicated for medically treated patients with ACS
Patients with NSTEMI already initiated on aspirin
Early coronary angiography/
early invasive strategy:
• First choice: ticagrelor*†
• Second choice: prasugrel†




Prasugrel is not recommended
*Recommendations for ticagrelor in patients with NSTEMI are based on the PLATO subgroup 
analysis examining patients presenting with NSTE-ACS, which included patients with NSTEMI and 
other ACS without ST-elevation.28 †Please refer to local prescribing information for dosing 
recommendations. ACS = acute coronary syndrome; CABG = coronary artery bypass graft; 
NSTE-ACS = non-ST-elevation ACS; NSTEMI = non-ST-elevation MI.
Figure 2: Treatment Algorithm for Patients with NSTEMI
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DAPT should not be stopped within 4 weeks of stenting unless it is for 
critical surgery. The ischaemic versus bleeding risk in patients treated 
with DAPT undergoing surgery must be weighed during pre-surgery 
discussions between the cardiologist and the proceduralist.
The Food and Drug Administration (FDA) and European Medicines 
Agency (EMA)-approved label states that ticagrelor should be stopped 
for up to 5 days prior to elective surgery.9, 10
While the European Society of Cardiology 2017 guidelines recommend 
stopping treatment up to 3 days prior to surgery based on the results of 
the ONSET/OFFSET study, the panel does not support this 
recommendation because it is based on a single study.3,50 Clopidogrel 
and prasugrel treatment should be stopped 5 and 7 days before surgery, 
respectively.3
Switching Antiplatelet Therapy
Statement 11. Clinicians must evaluate reasons for de-escalation 
and weigh these against the risk of a possible ischaemic event. If 
de-escalation is necessary, this should be delayed for as long as 
possible (at least 1 month, but preferably >3 months after the ACS 
event) as risk of ischaemic events in revascularised patients 
decreases over time.
Level of evidence: Low.
Level of agreement: 86.4% agree, 13.7% neutral, 4.5% disagree.
Statement 12. Regardless of time frame, reloading is required when 
switching from ticagrelor or prasugrel to clopidogrel unless there is 
on-going bleeding. 
Level of evidence: Very low.
Level of agreement: 81.9% agree, 4.5% neutral, 13.6% disagree.
DAPT should be continued for a minimum of 12 months, unless 
contraindicated or not tolerated.2,3 De-escalation (change from ticagrelor 
or prasugrel to clopidogrel) may be required due to major bleeding, 
ambiguity surrounding dose requirements for elderly patients/patients 
with low body weight using prasugrel, or cost.51–53
De-escalation of ticagrelor or prasugrel to clopidogrel may reduce the 
risk of bleeding without compromising efficacy.54 However, observational 
data from Asian patients have suggested that de-escalating DAPT in the 
absence of platelet-function-testing-guided clopidogrel dosing may 
increase the risk of ischaemic events without reducing bleeding 
risk.38,51,53,55
If de-escalation to clopidogrel is necessary, de-escalation should be 
delayed as long as possible, preferably until >3 months after an ACS, and 
avoided <1 month after the event,56 because of the time-dependent 
decrease in the risk of ischaemic events following an ACS. 
Data from patients who de-escalate DAPT is limited and a consensus on a 
de-escalation strategy has not been reached in the literature. 
To guide practice despite the lack of strong evidence, the panel consensus 
is to consider a 600 mg loading dose of clopidogrel when de-escalating 
from ticagrelor to clopidogrel, irrespective of time from ACS. However, 
directly de-escalating to a 75 mg daily maintenance dose of clopidogrel is 
reasonable when de-escalation is due to bleeding.57 
Long-term Versus Short-term 
Dual Antiplatelet Therapy 
Statement 13. The standard duration of DAPT is 12 months after an 
ACS. Extension of DAPT beyond 1 year may be considered for high 
ischaemic-risk patients, such as those with high-risk stent anatomy, 
complex coronary anatomy or additional risk factors (e.g. diabetes). 
Clinicians must evaluate both ischaemic and bleeding risk.
Level of evidence: High.
Level of agreement: 85.5% agree, 0.0% neutral, 4.5% disagree.
Continuing DAPT with clopidogrel beyond 12 months has been shown to 
decrease the risk of ischaemic events, including CV death, among high-
risk patients with a history of MI versus aspirin alone, but is associated 
with an increased risk of major bleeding.58 Similar outcomes when 
continuing DAPT with ticagrelor (60 or 90 mg) beyond 12 months were 
reported in the PEGASUS-TIMI 54 trial, although there was no significant 
increase in the rate of fatal bleeding or intracranial haemorrhage.14 The 
FDA and EMA licensed the use of ticagrelor 60 mg from 12–36 months 
because of its comparable efficacy but lower risk of bleeding versus a 
90-mg dose.9,10 DAPT using ticagrelor 60 mg beyond 12 months has also 
demonstrated a benefit compared with placebo in patients with 
concomitant multivessel disease or diabetes.59,60
Genotyping, CYP2C19 Polymorphisms 
and Platelet Function Testing
Statement 14. Due to the lack of positive prospective trials in Asian 
patients, the routine use of point-of-care platelet function testing to 
guide decisions in antiplatelet therapy is not recommended. 
Level of evidence: Very low.
Level of agreement: 100% agree, 0.0% neutral, 0.0% disagree.
Patients with a CYP2C19 poor metaboliser phenotype may not achieve 
adequate platelet inhibition with the CYP219-dependent prodrug 
clopidogrel.5 In contrast, ticagrelor and prasugrel are not dependent on 
CYP2C19 bioactivation,5 but differences in bioactivation alone do not 
fully account for the reduced risk of ischaemic events with ticagrelor 
versus clopidogrel.61
CYP2C19 polymorphism-guided antiplatelet prescribing may improve 
clinical outcomes for patients with ACS and offers a cost-effective 
approach to treatment.62–64 Point-of-care platelet function testing may also 
act as a surrogate marker for CYP2C19 polymorphisms for patients 
administered clopidogrel.65 Nonetheless, despite the high prevalence of 
CYP2C19 polymorphisms in the Asia-Pacific region, routine use of 
genotype-guided DAPT is not recommended because of the lack of 
prospective randomised trials performed in the Asia-Pacific region 
demonstrating a clinical benefit, though further research is warranted.5,65,66
Special Populations
Statement 15. Ticagrelor has been shown to be effective and safe 
among specific populations (diabetes, elderly and chronic kidney 
disease [CKD]) with ACS. 
Level of evidence: Moderate.
Level of agreement: 89.9% agree, 9.1% neutral, 0.0% disagree.
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Caution and clinical judgment must be exercised when using DAPT in 
patients with comorbidities associated with an increased risk of ischaemic 
events and/or bleeding, such as diabetes or CKD, and in elderly patients 
(age >75 years).67–69 No dose adjustment is required for ticagrelor.9,10 A 
reduced 5 mg daily dose of prasugrel is required for patients weighing <60 
kg and prasugrel is not recommended for patients aged ≥75 years.8,67–69
Future Directions
Spontaneous major bleeding and bleeding associated with urgent invasive 
procedures remain concerns for patients administered DAPT following an 
ACS. In particular, the antiplatelet effects of ticagrelor cannot be reversed 
with platelet transfusion.70 A candidate reversal agent is PB2452 (PhaseBio 
Pharmaceuticals), a monoclonal antibody fragment that binds ticagrelor, is 
under investigation and has demonstrated immediate and sustained 
reversal of the antiplatelet effects of ticagrelor in a phase 1 study.70
Efforts to prospectively investigate the efficacy and safety of CYP2C19 
polymorphism-guided antiplatelet prescribing in Asia, and subsequent 
cost-effectiveness analyses, would be welcomed given the economic 
considerations that drive antiplatelet prescribing in the region. 
Limitations 
The breadth of literature on the role of ticagrelor, prasugrel, and 
clopidogrel in ACS is diverse and these consensus recommendations are 
not exhaustive and are based on the best available evidence at the time 
of publication. The consensus statements are not intended to replace 
clinical judgement. Furthermore, the use of P2Y12 inhibitors in patients 
receiving oral anticoagulants due to concomitant AF was not discussed, 
and is discussed in another consensus document.
Conclusion
When managing Asian patients who have had an ACS with DAPT, there 
are different considerations compared with those for Western 
populations. While data from Asian populations comparing outcomes 
with ticagrelor, prasugrel, and clopidogrel are limited, there is evidence 
to suggest that ticagrelor or prasugrel should be preferred over 
clopidogrel for most patients with ACS, particularly those who have 
undergone PCI. The decision on duration of DAPT – including the need 
to de-escalate, stop or continue therapy beyond 12 months – should be 
individualised, considering both the ischaemic and bleeding risk for 
each patient. 
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